The identification and management of heparin-induced thrombocytopenia in the vascular patient
Narrative review published in Journal of vascular surgery (2012)
Abstract
Heparin-induced thrombocytopenia (HIT) is a serious, acquired, prothrombotic disorder caused by an antibody response to the heparin-platelet factor 4 complex, which can precipitate arterial as well as venous thromboembolic complications. HIT should be suspected in patients exposed to heparin who present with an unexplained thrombosis or a significant drop in platelet count, or both. Once HIT is suspected or identified, there are specific approaches to its diagnosis and management, with emphasis on removal of all heparin compounds and administration of alternative nonheparin anticoagulants. Generally, HIT is a self-limiting syndrome that resolves when the antibody titers disappear. Patients should be anticoagulated for up to 6 months, depending on the clinical scenario; however, the management of patients with remote or recent HIT requiring a vascular procedure requires special considerations.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Review of recognizing and managing heparin-induced thrombocytopenia in vascular patients: suspect HIT with unexplained thrombosis or platelet fall, stop all heparin, start non-heparin anticoagulants, and treat up to 6 months; vascular procedures need special considerations.
Why This Matters for Hirudotherapy
This review explains how heparin-induced thrombocytopenia (HIT), an antibody response to the heparin-platelet factor 4 complex, can cause arterial and venous thrombosis, and outlines its diagnosis and management, emphasizing removal of all heparin and substitution with non-heparin anticoagulants, with special considerations for vascular-surgery patients. Its relevance to ASH lies in motivating the search for anticoagulants outside the heparin class: leech-derived inhibitors such as hirudin and related secretome molecules act by mechanisms distinct from heparin and are conceptually attractive where heparin is contraindicated by HIT. Caveat: this is a narrative clinical review summarizing existing practice, not new research, and it neither studies nor recommends medicinal-leech therapy; it should be read as context for why heparin-alternative agents matter, not as support for hirudotherapy in HIT.
Citation
The identification and management of heparin-induced thrombocytopenia in the vascular patient.
LaMuraglia et al. · Journal of vascular surgery, 2012
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026